Taking on Monopoly Power: Patent Reform

"I Wasn’t a ‘Bad Diabetic.’ I Just Couldn’t Afford Insulin."

11 Jun 2025, 5:06 p.m. in Content Type: Advocacy Stories, Country: United States, Taking on Monopoly Power: Patent Reform by Lacy McGee

U.S. Action 2025: Circus of Pharma Greed!

3 Feb 2025, 11:58 p.m. in Action & Workshop, Content Type: News & Statements, Country: United States, Taking on Monopoly Power: Patent Reform by T1International

T1International Invited to White House Event

22 Apr 2024, 6:21 p.m. in Content Type: Advocacy Stories, Country: United States, Insulin Access: Price Caps, Taking on Monopoly Power: Patent Reform by T1International

T1International advocates, Jesús Morales Sánchez (Communities of Color Working Group Co-Leader), Kristen Whitney Daniels (Federal Working Group Co-Leader), Lib Gatti (USA Advocacy Manager), and Shaina Kasper (Policy and Advocacy Director), were honored to be invited to a recent event at the White House focused on lowering healthcare costs. The event celebrated the success of the access to medicines movement in achieving a $35 monthly cap on out-of-pocket costs for insulin for Medicare Part D beneficiaries, allowing Medicare to negotiate drug prices directly with pharmaceutical companies, and more. Read more

Three Reasons Why is Insulin STILL So Expensive

29 Aug 2023, 4:49 p.m. in Contains: Resource, Country: Global, Insulin Access: Alec's Law, Insulin Access: Kevin's Law, Insulin Access: Modern Insulins, Insulin Access: Price Caps, Taking on Monopoly Power: Patent Reform, Taking on Monopoly Power: Public Pharma by Shaina Kasper

Over the past few months, many insulin manufacturers and other entities have announced that they will be lowering the price of insulin in the United States. So, why is insulin still so expensive?
We recently released our Policy Playbook that goes through all of the details and gives advocates the information to push for change locally and nationally. Why insulin is so expensive can be boiled down to three main points. Read more